Ovid TherapeuticsOVID
About: Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
Employees: 25
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
262% more call options, than puts
Call options by funds: $47K | Put options by funds: $13K
107% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 15
54% more capital invested
Capital invested by funds: $29.7M [Q2] → $45.8M (+$16.1M) [Q3]
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
1% more funds holding
Funds holding: 73 [Q2] → 74 (+1) [Q3]
0.31% more ownership
Funds ownership: 54.35% [Q2] → 54.66% (+0.31%) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Raghuram Selvaraju 45% 1-year accuracy 105 / 232 met price target | 191%upside $3 | Buy Reiterated | 4 Dec 2024 |
HC Wainwright & Co. Raghuram Selvaraju 45% 1-year accuracy 105 / 232 met price target | 191%upside $3 | Buy Reiterated | 30 Sept 2024 |